JP2006511520A5 - - Google Patents

Download PDF

Info

Publication number
JP2006511520A5
JP2006511520A5 JP2004559355A JP2004559355A JP2006511520A5 JP 2006511520 A5 JP2006511520 A5 JP 2006511520A5 JP 2004559355 A JP2004559355 A JP 2004559355A JP 2004559355 A JP2004559355 A JP 2004559355A JP 2006511520 A5 JP2006511520 A5 JP 2006511520A5
Authority
JP
Japan
Prior art keywords
prophylaxis
inhibiting
risk
reducing
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004559355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006511520A (ja
Filing date
Publication date
Priority claimed from US10/316,424 external-priority patent/US20040115265A1/en
Application filed filed Critical
Publication of JP2006511520A publication Critical patent/JP2006511520A/ja
Publication of JP2006511520A5 publication Critical patent/JP2006511520A5/ja
Pending legal-status Critical Current

Links

JP2004559355A 2002-12-11 2003-12-03 プラバスタチンおよびアスピリン含有多層錠および方法 Pending JP2006511520A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/316,424 US20040115265A1 (en) 2002-12-11 2002-12-11 Multilayered tablet containing pravastatin and aspirin and method
PCT/US2003/038774 WO2004052289A2 (en) 2002-12-11 2003-12-03 Multilayered tablet containing pravastatin and aspirin

Publications (2)

Publication Number Publication Date
JP2006511520A JP2006511520A (ja) 2006-04-06
JP2006511520A5 true JP2006511520A5 (cg-RX-API-DMAC7.html) 2006-12-14

Family

ID=32505946

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004559355A Pending JP2006511520A (ja) 2002-12-11 2003-12-03 プラバスタチンおよびアスピリン含有多層錠および方法

Country Status (17)

Country Link
US (1) US20040115265A1 (cg-RX-API-DMAC7.html)
EP (1) EP1581194B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006511520A (cg-RX-API-DMAC7.html)
AT (1) ATE401061T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003297689A1 (cg-RX-API-DMAC7.html)
CY (1) CY1108414T1 (cg-RX-API-DMAC7.html)
DE (1) DE60322264D1 (cg-RX-API-DMAC7.html)
DK (1) DK1581194T3 (cg-RX-API-DMAC7.html)
ES (1) ES2308040T3 (cg-RX-API-DMAC7.html)
IS (1) IS2877B (cg-RX-API-DMAC7.html)
MY (1) MY140947A (cg-RX-API-DMAC7.html)
NO (1) NO338696B1 (cg-RX-API-DMAC7.html)
PL (1) PL206190B1 (cg-RX-API-DMAC7.html)
PT (1) PT1581194E (cg-RX-API-DMAC7.html)
SI (1) SI1581194T1 (cg-RX-API-DMAC7.html)
TW (1) TWI361700B (cg-RX-API-DMAC7.html)
WO (1) WO2004052289A2 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
US8163797B2 (en) * 2003-12-31 2012-04-24 Actavis Elizabeth Llc Method of treating with stable pravastatin formulation
WO2006072054A1 (en) * 2004-12-30 2006-07-06 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
US20060251722A1 (en) * 2005-05-03 2006-11-09 Novavax, Inc. Multi-component vitamin and mineral supplement for the optimal absorption of components
JP2009507019A (ja) * 2005-09-02 2009-02-19 ジェンザイム・コーポレーション リン酸塩を除去する方法およびそれに使用される重合体
CA2626734A1 (en) * 2005-11-08 2007-05-18 Genzyme Corporation Magnesium-containing polymers for the treatment of hyperphosphatemia
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
WO2007072060A2 (en) * 2005-12-23 2007-06-28 Cipla Limited Particles comprising a core containing a hmg-coa reductase inhibitor and coated with a film
EP1970055B1 (en) 2005-12-29 2010-11-24 Osmotica Kereskedelmi És Szolgáltató Kft Multi-layered tablet with triple release combination
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20100135950A1 (en) * 2006-07-05 2010-06-03 Genzyme Corporation Iron(II)-Containing Treatments for Hyperphosphatemia
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
DE602007005402D1 (de) * 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
ES2579229T3 (es) 2007-03-13 2016-08-08 Jds Therapeutics, Llc Procedimientos y composiciones para la liberación sostenida de cromo
WO2009002867A2 (en) * 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US8481083B2 (en) * 2007-10-12 2013-07-09 Ferring International Center S.A. Granular compositions of magnesium oxide and citric acid and uses thereof
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
TR201005325A2 (tr) 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
KR20120068277A (ko) * 2010-12-17 2012-06-27 한미사이언스 주식회사 HMG-CoA 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제
US8718837B2 (en) * 2011-01-28 2014-05-06 Intouch Technologies Interfacing with a mobile telepresence robot
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
AU2017217466A1 (en) 2016-02-11 2018-08-23 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
JP7109748B2 (ja) * 2018-12-11 2022-08-01 日本ジェネリック株式会社 アジルサルタンとアムロジピンベシル酸塩含有固形製剤及び固形製剤の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590183A (en) * 1985-04-22 1986-05-20 Sterling Drug Inc. Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin
JP3172749B2 (ja) * 1992-02-17 2001-06-04 ライオン株式会社 イブプロフェン含有製剤
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
WO1999047128A1 (en) * 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Similar Documents

Publication Publication Date Title
WO2005082863A3 (en) 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors
ATE516285T1 (de) Dihydropyridinonderivate
NO20071930L (no) t4Metoder og sammensetninger til behandling av hyperlipidemi.
PL2482078T3 (pl) Diagnozowanie choroby sercowo-naczyniowej
NO20070247L (no) Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase
IL189500A (en) 4, 2-Diaminopyrimidines are preserved in position 5, containing pharmaceutical preparations and using them to prepare a drug for the treatment of 3x2p receptor mediated diseases and 2/3 x2p
DE50311502D1 (de) Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
GB0412753D0 (en) Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis
LT2878297T (lt) Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai
NO20041452L (no) 17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer.
NO20053860D0 (no) COP 1 for behandling av inflammatorisk tarmsykdom.
WO2006034003A3 (en) Compounds, compositions and methods of inhibiting a-synuclein toxicity
WO2003031650A3 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
EP1635815A4 (en) METHOD AND COMPOUNDS FOR TREATING TISSUE TESTS
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
GB0514501D0 (en) Pharmaceutical compounds
NO20100477L (no) Anvendelse av risendronat til fremstilling av medikamenter for behandling og prevensjon av osteoporose
WO2006025924A3 (en) Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof
WO2004024167A3 (fr) Utilisation de prebiotiques, preferentiellement le glucooligosaccharide, pour la prevention de l’installation du diabete de type ii
ZA200104616B (en) Diazepinoindoles for the treatment of chronic obstructive pulmonary disease.
DE602006012332D1 (de) Kombination von verbindungen, die bei der behandlung von atemwegserkrankungen verwendet werden können, insbesondere bei chronisch obstruktiver lungenerkrankung (copd) und asthma
WO2006138043A3 (en) Method and compositions for the treatment of diabetes and related complications
EP1896074A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF CORONARY ARTERY DISEASE
JP2007512260A5 (cg-RX-API-DMAC7.html)
EP1543166A4 (en) SYNERGETIC COMPOSITIONS FOR PREVENTING AND TREATING THE ACQUIRED IMMUNE WEAKNESS SYNDROME